Home
NewsNewsMemphasys has confirmed a Felix System Nordic expansion into Denmark, Sweden, Norway, Finland, and Iceland through an exclusive agreement with fertility-technology distributor NOVIVITAE ApS. The deal carries minimum contracted purchases of €526,500 across three years, with an initial order of €20,625 and three Felix™ consoles to be supplied in the September 2026 quarter.
Memphasys has expanded the European commercial footprint of its Felix™ System into Denmark, Sweden, Norway, Finland, and Iceland through an exclusive agreement with Nordic fertility-technology distributor NOVIVITAE ApS.
The Felix System Nordic expansion carries minimum contracted purchases of €526,500 across three agreement years, following a three-month evaluation period. An initial order valued at €20,625, together with three Felix™ consoles, is to be supplied and invoiced in the September quarter.
The five new markets take Felix™ commercial activity or agreements in Europe to nine countries, alongside Italy, the United Kingdom, Türkiye, and Poland. The expansion gives Memphasys a broader base from which to build clinic engagement and recurring cartridge demand across the continent.
Each Felix™ procedure uses a single disposable cartridge which means the commercial opportunity depends not only on placing consoles but also on clinics adopting the system and using it consistently. The agreement supports that progression through quarterly ordering requirements and rising minimum purchase commitments after the evaluation period concludes.
The latest comparable country-level data identified by Memphasys recorded approximately 55,000 assisted reproductive technology treatment cycles across the five Nordic countries in 2020. That period was affected by COVID-19 and serves as a historical benchmark rather than a current market forecast.
NOVIVITAE ApS supplies products and services to IVF clinics and sperm and egg banks across the Nordic region. Under the agreement, its responsibilities will span product demonstrations, training, scientific workshops, clinic engagement, and first-line customer support.
These activities are central to the agreement's commercial logic. Regulatory access and a signed distribution deal do not by themselves establish routine clinical use converting interest into consistent utilisation and repeat cartridge orders requires sustained on-the-ground engagement with clinical teams. NOVIVITAE's established presence across the five markets positions it to carry out that work.
A new Ipsos survey commissioned by Fertility Matters Canada finds 49% of Canadians with an opinion support a national baseline for IVF funding support, with backing rising to 59% among those aged 18–34. One in eight Canadians say cost has already forced them or someone close to delay or abandon fertility treatment.
Alpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
